ES2542694T3 - Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta - Google Patents

Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta Download PDF

Info

Publication number
ES2542694T3
ES2542694T3 ES08718009.7T ES08718009T ES2542694T3 ES 2542694 T3 ES2542694 T3 ES 2542694T3 ES 08718009 T ES08718009 T ES 08718009T ES 2542694 T3 ES2542694 T3 ES 2542694T3
Authority
ES
Spain
Prior art keywords
omega
fatty acids
masked
copper
copper salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08718009.7T
Other languages
English (en)
Inventor
Georg Ludwig Kis
Jacques Vandermander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39477329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2542694(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07104792A external-priority patent/EP1974733A1/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2542694T3 publication Critical patent/ES2542694T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Una composición farmacéutica que comprende uno o más ácidos grasos omega 3 sensibles al cobre y una sal de cobre enmascarada o recubierta para estabilizar la composición farmacéutica frente a la descomposición dependiente de la sal de cobre.

Description

imagen1
E08718009
15-07-2015
Gelatina 175 bloom bovina Glicerol al 99 %,USP Aceite de soja en copos (hidrogenado), NF Aceite de soja USP y
Colorantes (si es necesario) orgánicos y/o inorgánicos, por ejemplo, dióxido de titanio USP, óxido de hierro negro E172 y/o óxido de hierro rojo E172
La estabilidad de la composición anterior se investiga en un entorno donde el cobre no está enmascarado y en una
5 situación en la que el cobre está enmascarado en la cubierta y que, por consiguiente, no está en contacto directo con los ingredientes sensibles al cobre. La estabilidad del procedimiento de enmascaramiento/recubrimiento descrito se correlaciona con el grado de descomposición de tal compuesto y/o composición sensibles al cobre.
Ejemplo 3
240 mg de aceite de pescado con DHA al 70 % etiquetado 160 mg de ácidos grasos omega 3Ácido docosahexaenoico (DHA) etiquetado 130 mg de DHAÁcido eicosapentaenoico (EPA) como parte del aceite de pescado etiquetado 11 mg 91,5 mg de ascorbato de calcio etiquetado 60 mg de vitamina C 31,343 mg de acetato de d,l-alfa-tocoferol etiquetado 20 mg de vitamina E 55 mg de luteína al 20 % en aceite de alazor etiquetado 10 mg de luteína 12,447 mg de óxido de cinc etiquetado 10 mg de cinc 0,45 mg de carbonato cúprico básico etiquetado 0,25 mg de cobre Zeaxantina como parte de la luteína etiquetado 0,8 mg
La composición anterior puede contener otros excipientes para la producción de una formulación galénica deseada, 10 por ejemplo, para fabricar una cubierta de una cápsula o similar.
Ejemplo 4
Estabilidad de ácidos grasos omega 3 en cápsulas blandas de gelatina después de 2 días de almacenamiento a 80 [grados] C. (Humedad ambiental, es decir, humedad relativa del 50-70 %)
(Cambio en el contenido de los componentes de ácido graso omega 3)
15 Los ensayos para cuantificar el porcentaje en peso de EPA y DHA después del almacenamiento se llevan a cabo por cromatografía de gases por el procedimiento habitual descrito en la Farmacopea Europea 5.4.
Componentes de ácidos grasos omega 3
Formulación con cobre no enmascarado Formulaciones con cobre enmascarado
Formulaciones desveladas en el ejemplo 3: (con carbonato cúprico básico). La cubierta es idéntica a la cubierta desvelada en el ejemplo 2, pero no contiene cobre
Formulación como se desvela en el ejemplo 3, en la que se reemplaza el carbonato cúprico básico con 2,250 mg de DESCOTE® (gluconato de cobre recubierto), que corresponden a 0,25 mg de cobre. La cubierta es idéntica a la cubierta desvelada en el ejemplo 2, pero no contiene cobre Formulación desvelada en el ejemplo 3, si bien se omite el cobre de dicha formulación. No obstante hay cobre en la cubierta, a saber, 0,45 mg de carbonato cúprico básico (que corresponden a 0,25 mg de cobre), como se desvela en el ejemplo 2
EPA en % en peso
disminución del 5,0 % disminución del 1,7 % sin cambios (sin disminución)
DHA en % en peso
Sin cambios detectables Sin cambios detectables sin cambios (sin disminución)
Otros ácidos grasos omega 3** distintos de EPA y DHA en % en peso
disminución del 1,9 % disminución del 0,4 % sin cambios (sin disminución)
**Otros ácidos grasos omega 3 denota la suma de ácido alfa-linolénico (ALA), ácido estearidónico (SA), ácido eicosatetraenoico (ETA) y ácido docosapentaenoico (DPA).
3
imagen2

Claims (1)

  1. imagen1
ES08718009.7T 2007-03-23 2008-03-19 Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta Active ES2542694T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07104792 2007-03-23
EP07104792A EP1974733A1 (en) 2007-03-23 2007-03-23 Use of a masked or coated copper salt for the treatment of macular degeneration
EP07111322 2007-06-28
EP07111322 2007-06-28
PCT/EP2008/053283 WO2008116806A1 (en) 2007-03-23 2008-03-19 Use of a masked or coated copper salt for the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
ES2542694T3 true ES2542694T3 (es) 2015-08-10

Family

ID=39477329

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08718009.7T Active ES2542694T3 (es) 2007-03-23 2008-03-19 Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta

Country Status (26)

Country Link
US (1) US20080233182A1 (es)
EP (1) EP2124973B1 (es)
JP (1) JP2010521534A (es)
KR (1) KR101688656B1 (es)
AR (1) AR065791A1 (es)
AU (1) AU2008231847B2 (es)
BR (1) BRPI0809258B8 (es)
CA (1) CA2681514C (es)
CL (1) CL2008000804A1 (es)
CO (1) CO6230993A2 (es)
DK (1) DK2124973T3 (es)
EC (1) ECSP099700A (es)
ES (1) ES2542694T3 (es)
GT (1) GT200900251A (es)
IL (1) IL201109A (es)
MA (1) MA31293B1 (es)
MX (1) MX2009010244A (es)
MY (1) MY164520A (es)
NZ (1) NZ579852A (es)
PE (1) PE20090186A1 (es)
PL (1) PL2124973T3 (es)
PT (1) PT2124973E (es)
RU (1) RU2009139002A (es)
TN (1) TN2009000387A1 (es)
TW (1) TW200904456A (es)
WO (1) WO2008116806A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019500030A1 (en) * 2009-03-09 2020-02-10 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
KR101759255B1 (ko) 2015-09-18 2017-07-18 한국산업기술대학교산학협력단 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043487A1 (es) * 1969-05-28 1971-02-19 Commissariat Energie Atomique
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US20030004043A1 (en) * 2001-06-27 2003-01-02 Deola James A. Pivoting backrest for exercise apparatus
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
WO2005110375A1 (en) * 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
EP1614414A3 (en) * 2004-07-09 2008-07-09 Robert Sabin Compositions comprising a copper compound for treatment of mammalian diseases
AU2005306320B2 (en) * 2004-11-19 2011-09-08 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Also Published As

Publication number Publication date
IL201109A0 (en) 2010-05-17
EP2124973A1 (en) 2009-12-02
EP2124973B1 (en) 2015-05-27
TW200904456A (en) 2009-02-01
MY164520A (en) 2017-12-29
KR101688656B1 (ko) 2016-12-21
GT200900251A (es) 2018-10-08
AR065791A1 (es) 2009-07-01
JP2010521534A (ja) 2010-06-24
CL2008000804A1 (es) 2008-10-24
CA2681514A1 (en) 2008-10-02
CO6230993A2 (es) 2010-12-20
BRPI0809258B8 (pt) 2021-05-25
RU2009139002A (ru) 2011-04-27
MX2009010244A (es) 2009-10-26
TN2009000387A1 (en) 2010-12-31
MA31293B1 (fr) 2010-04-01
AU2008231847A1 (en) 2008-10-02
PE20090186A1 (es) 2009-03-20
US20080233182A1 (en) 2008-09-25
DK2124973T3 (da) 2015-06-22
NZ579852A (en) 2012-03-30
KR20100015799A (ko) 2010-02-12
CA2681514C (en) 2016-11-08
WO2008116806A1 (en) 2008-10-02
BRPI0809258A2 (pt) 2014-09-23
IL201109A (en) 2016-10-31
AU2008231847B2 (en) 2012-12-06
PT2124973E (pt) 2015-09-01
ECSP099700A (es) 2009-11-30
PL2124973T3 (pl) 2015-10-30
BRPI0809258B1 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
Elagizi et al. Omega-3 polyunsaturated fatty acids and cardiovascular health: a comprehensive review
de Barboza et al. Oxidative stress, antioxidants and intestinal calcium absorption
Barcelos et al. Effects of ω-3 essential fatty acids (ω-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter
Trebatická et al. Cardiovascular diseases, depression disorders and potential effects of omega-3 fatty acids
Kumar et al. Hesperidin potentiates the neuroprotective effects of diazepam and gabapentin against pentylenetetrazole-induced convulsions in mice: Possible behavioral, biochemical and mitochondrial alterations
RU2009126735A (ru) Композиция питательной добавки, предназначенной для лечения глазных болезней
MXPA06008352A (es) Una composicion farmaceutica.
EP3738586A1 (en) Enteric soft capsules comprising polyunsaturated fatty acids
CO6470839A2 (es) Composiciones farmacéuticas que contienen epa y un agente cardiovascular y métodos de emplearlas
EA200100895A1 (ru) Незаменимые жирные кислоты для предотвращения сердечно-сосудистых приступов
RU2008103281A (ru) Способы и композиции для профилактики и лечения воспалительного заболевания
EP2217220B1 (en) Lipoic acid pellet composition
RU2007117803A (ru) Композиция для лечения глаз, содержащая омега-3 жирные кислоты и омега-6 жирные кислоты
EP1714658B1 (fr) Complément alimentaire comprenant une association d'agents antioxydants et de la carnitine ou un précurseur de la carnitine, comme aide à la fertilité chez l'homme et chez la femme
ES2542694T3 (es) Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta
Jabłońska-Trypuć et al. Traumatic acid toxicity mechanisms in human breast cancer MCF-7 cells
Nasadyuk et al. Thymohexin exhibits cytoprotective effect in experimental gastric lesions in rats both through the inhibition of inducible nitric oxide synthase and reduction of oxidative mucosal damage
Tenore et al. Canned bluefin tuna, an in vitro cardioprotective functional food potentially safer than commercial fish oil based pharmaceutical formulations
FR3068603A1 (fr) Complement alimentaire pour proteger la fertilite feminine et masculine
Das Bioactive lipids as mediators of the beneficial actions of statins
AR070405A1 (es) Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual
Mohamed et al. Effects of simultaneous melatonin administration on the testis of the experimentally induced hyper-and hypothyroidism in the adult male albino rat
Siriviriyakul et al. The vascular effect of genistein: What is its mechanism, nitric oxide or PGI 2?
FR2760358A1 (fr) Composition cosmetique et pharmaceutique revigorante, notamment permettant d'eviter aux cheveux de devenir blancs avec l'âge, et aussi de reprendre leur couleur d'origine s'ils sont deja blancs
ITFI20120288A1 (it) Formulazione farmaceutica comprendente inositolo e selenio, sua preparazione ed uso.